Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arkema S.A. stock logo
ARKAY
Arkema
$104.69
+3.2%
$104.02
$85.58
$114.15
$7.86B1.381,740 shs18,837 shs
CapitaLand Limited stock logo
CLLDY
CapitaLand
$6.21
+3.4%
$6.21
$3.65
$6.31
$16.16B1.0710,943 shs3,800 shs
Disco Co. stock logo
DSCSY
Disco
$30.93
-2.4%
$33.83
$10.94
$38.73
$33.52B1.12131,281 shs43,171 shs
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
$16.05
+2.1%
$15.65
$14.36
$23.67
$3.73B0.2714,293 shs4,437 shs
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
$22.33
$24.15
$21.28
$27.15
$4.92B0.5700 shsN/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arkema S.A. stock logo
ARKAY
Arkema
+3.18%+1.35%+1.29%-3.15%+5.74%
CapitaLand Limited stock logo
CLLDY
CapitaLand
0.00%0.00%0.00%0.00%0.00%
Disco Co. stock logo
DSCSY
Disco
-2.43%-12.58%-14.25%+13.71%+150.45%
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
+2.10%+3.95%+2.59%-0.62%-30.52%
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
0.00%-7.92%-4.45%-8.95%+8.19%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arkema S.A. stock logo
ARKAY
Arkema
N/AN/AN/AN/AN/AN/AN/AN/A
CapitaLand Limited stock logo
CLLDY
CapitaLand
N/AN/AN/AN/AN/AN/AN/AN/A
Disco Co. stock logo
DSCSY
Disco
0.8991 of 5 stars
0.03.00.80.02.50.01.9
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
0.4932 of 5 stars
0.03.02.50.00.60.01.3
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arkema S.A. stock logo
ARKAY
Arkema
3.00
BuyN/AN/A
CapitaLand Limited stock logo
CLLDY
CapitaLand
N/AN/AN/AN/A
Disco Co. stock logo
DSCSY
Disco
3.00
BuyN/AN/A
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
N/AN/AN/AN/A
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
2.00
HoldN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arkema S.A. stock logo
ARKAY
Arkema
$10.30B0.76$27.12 per share3.86$103.04 per share1.02
CapitaLand Limited stock logo
CLLDY
CapitaLand
$4.74B3.41N/AN/A$13.31 per share0.47
Disco Co. stock logo
DSCSY
Disco
$2.15B15.60$0.63 per share49.04$2.38 per share13.00
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
$3.36B1.11$1.80 per share8.91$12.64 per share1.27
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
$2.88B1.71$3.33 per share6.71$10.03 per share2.23

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arkema S.A. stock logo
ARKAY
Arkema
$452.36M$5.8018.059.880.454.40%8.92%4.76%N/A
CapitaLand Limited stock logo
CLLDY
CapitaLand
-$1.14BN/A0.00N/AN/AN/AN/AN/A
Disco Co. stock logo
DSCSY
Disco
$613.40MN/A0.0045.49N/AN/AN/AN/AN/A
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
$396.25MN/A0.007.72N/AN/AN/AN/AN/A
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
$190MN/A0.009.71N/AN/AN/AN/AN/A

Latest ARKAY, HKMPF, HEGIY, CLLDY, and DSCSY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/29/202412/31/2023
Arkema S.A. stock logo
ARKAY
Arkema
$1.87$1.54-$0.33$2.79$2.44 billion$2.39 billion
1/24/2024Q3 2024
Disco Co. stock logo
DSCSY
Disco
N/A$0.15+$0.15$0.20N/A$521.41 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arkema S.A. stock logo
ARKAY
Arkema
$3.102.96%N/A53.45%N/A
CapitaLand Limited stock logo
CLLDY
CapitaLand
$0.121.93%N/AN/AN/A
Disco Co. stock logo
DSCSY
Disco
$0.070.23%N/AN/AN/A
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
$0.875.42%N/AN/AN/A
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
$0.944.21%N/AN/AN/A

Latest ARKAY, HKMPF, HEGIY, CLLDY, and DSCSY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/6/2024
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
$0.473/20/20243/22/20245/3/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arkema S.A. stock logo
ARKAY
Arkema
0.40
2.25
1.64
CapitaLand Limited stock logo
CLLDY
CapitaLand
0.79
0.95
0.95
Disco Co. stock logo
DSCSY
Disco
N/A
2.65
1.68
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
N/AN/AN/A
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
0.47
1.57
0.90

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Arkema S.A. stock logo
ARKAY
Arkema
N/A
CapitaLand Limited stock logo
CLLDY
CapitaLand
N/A
Disco Co. stock logo
DSCSY
Disco
0.03%
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
0.01%
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Arkema S.A. stock logo
ARKAY
Arkema
21,10075.04 millionN/ANot Optionable
CapitaLand Limited stock logo
CLLDY
CapitaLand
10,4732.60 billionN/ANot Optionable
Disco Co. stock logo
DSCSY
Disco
4,5531.08 billionN/ANot Optionable
Hengan International Group Company Limited stock logo
HEGIY
Hengan International Group
23,000232.42 millionN/ANot Optionable
Hikma Pharmaceuticals PLC stock logo
HKMPF
Hikma Pharmaceuticals
8,800220.23 millionN/ANot Optionable

ARKAY, HKMPF, HEGIY, CLLDY, and DSCSY Headlines

SourceHeadline
Hikma Pharmaceuticals PLC goes ex dividend tomorrowHikma Pharmaceuticals PLC goes ex dividend tomorrow
msn.com - March 20 at 5:15 AM
Optimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past weekOptimism around Hikma Pharmaceuticals (LON:HIK) delivering new earnings growth may be shrinking as stock declines 3.3% this past week
finance.yahoo.com - March 18 at 7:54 AM
Hikma Pharmaceuticals PLC (HKMPF)Hikma Pharmaceuticals PLC (HKMPF)
finance.yahoo.com - February 27 at 4:02 PM
Drugmaker Hikma expects profit to be slightly lower in 2024Drugmaker Hikma expects profit to be slightly lower in 2024
msn.com - February 22 at 7:56 AM
Hikma Pharma FY Profit IncreasesHikma Pharma FY Profit Increases
markets.businessinsider.com - February 22 at 7:56 AM
Hikma divi boost sends stock 5% higherHikma divi boost sends stock 5% higher
proactiveinvestors.co.uk - February 22 at 3:52 AM
Hikma Pharma introduces Combogesic IV injection in USHikma Pharma introduces Combogesic IV injection in US
pharmabiz.com - February 6 at 7:57 AM
Hikma Pharmaceuticals: Notice of ResultsHikma Pharmaceuticals: Notice of Results
cbonds.com - February 6 at 7:57 AM
Hikma Pharmaceuticals did not report suspicious opioid orders for 15 years, NC Attorney General Josh Stein saysHikma Pharmaceuticals did not report suspicious opioid orders for 15 years, NC Attorney General Josh Stein says
msn.com - February 1 at 6:51 PM
Hikma Pharmaceuticals Agrees in Principle to Pay up to $115M in US Opioid SettlementHikma Pharmaceuticals Agrees in Principle to Pay up to $115M in US Opioid Settlement
marketwatch.com - February 1 at 1:51 PM
Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 millionAd firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
finance.yahoo.com - February 1 at 1:51 PM
UPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 millionUPDATE 1-Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million
finance.yahoo.com - February 1 at 1:51 PM
Hikma Pharmaceuticals PLCs (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?Hikma Pharmaceuticals PLC's (LON:HIK) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
finance.yahoo.com - January 29 at 9:27 AM
Hikma Pharmaceuticals: Company Secretary ChangeHikma Pharmaceuticals: Company Secretary Change
cbonds.com - December 30 at 8:41 AM
FTSE 100 Live: Stocks close subdued session little changedFTSE 100 Live: Stocks close subdued session little changed
proactiveinvestors.co.uk - November 7 at 12:18 PM
FTSE 100 Live: Stocks soar on hopes interest rates have peakedFTSE 100 Live: Stocks soar on hopes interest rates have peaked
proactiveinvestors.co.uk - November 2 at 1:47 PM
The one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past weekThe one-year decline in earnings might be taking its toll on Hikma Pharmaceuticals (LON:HIK) shareholders as stock falls 3.3% over the past week
finance.yahoo.com - October 5 at 11:59 AM
Stocks Open Lower, Weighed Down by Rising Bond YieldsStocks Open Lower, Weighed Down by Rising Bond Yields
finance.yahoo.com - October 3 at 10:37 AM
Rakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North AfricaRakuten Medical and Hikma Sign Exclusive Licensing Agreement for Alluminox™ Platform Cancer Treatment in the Middle East and North Africa
finance.yahoo.com - August 10 at 9:17 AM
Hikma Appoints Bill Larkins as President of Injectables BusinessHikma Appoints Bill Larkins as President of Injectables Business
marketwatch.com - August 9 at 4:33 AM
Hikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseasesHikma Ventures invests in Octave Bioscience, a precision care platform for Multiple Sclerosis and other neurodegenerative diseases
finance.yahoo.com - July 26 at 4:38 PM
Selling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 MonthsSelling Hikma Pharmaceuticals After A 40% Share Price Gain In 7 Months
msn.com - May 6 at 10:01 AM
Riad Mishlawi to become CEO of Hikma PharmaRiad Mishlawi to become CEO of Hikma Pharma
medicaldialogues.in - April 13 at 10:36 AM
Riad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLCRiad Mishlawi named Chief Executive Officer of Hikma Pharmaceuticals PLC
jordantimes.com - April 12 at 6:46 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Arkema logo

Arkema

OTCMKTS:ARKAY
Arkema S.A. manufactures and sells specialty chemicals and advanced materials worldwide. The company operates in three segments: Adhesive Solutions, Advanced Materials and Coating Solutions, and Intermediates. The Adhesive Solutions segment provides solutions for construction, renovation of buildings, DIY, durable goods, and packaging and non-woven applications; and supplies technologies used in building activities for businesses and individuals, including sealants, tiles, flooring adhesives and waterproofing systems, and technologies used in industry, which include automotive, textiles, glazing, flexible and rigid packaging, and hygiene markets. This segment also offers performance polymers, such as specialty polyamides, PVDF, polyimides, fluorospecialties, and polyetherketoneketone; and performance additives which includes molecular sieves, organic peroxides, thiochemicals, and hydrogen peroxide. The Advance Materials and Coating Solutions segment offers coating solutions, including comprising EU/US acrylics and coating resins; coating additives, such as sartomer photocure resins and coatex rheology additives. This segment also provides decorative paints, industrial coatings, and adhesives; and solutions for applications in the paper, superabsorbent, water treatment and oil and gas extraction, and 3D printing and electronics industries. The Intermediates segment provides fluorogases and acrylics; and industrial intermediate chemicals used in construction, refrigeration and air conditioning, automotive, coatings, and water treatment sectors. Arkema S.A. was incorporated in 2003 and is headquartered in Colombes, France.
CapitaLand logo

CapitaLand

OTCMKTS:CLLDY
CapitaLand is one of Asia's largest real estate companies headquartered and listed in Singapore. The company leverages its significant asset base, design and development capabilities, active capital management strategies, and extensive market network and operational capabilities to develop high-quality real estate products and services. Its diversified global real estate portfolio includes integrated developments, shopping malls, serviced residences, offices and homes. The Group focuses on Singapore and China as our core markets, while it continues to expand in markets such as Vietnam and Indonesia. The company also has one of the largest real estate fund management businesses with assets located in Asia.
Disco logo

Disco

OTCMKTS:DSCSY
Disco Corporation manufactures and sells precision cutting, grinding, and polishing machines in Japan and internationally. Its precision machines include dicing saws, laser saws, grinders, polishers, wafer mounters, die separators, surface planers, and waterjet saws. The company also offers precision processing tools, such as dicing blades, grinding wheels, and dry polishing wheels; and other products, such as accessory equipment. In addition, it is involved in the disassembly and recycling of precision cutting, grinding, and polishing machines, as well as provides training services for the maintenance and operation of its products. Further, the company leases precision machines; and purchases and sells used machines. Additionally, it manufactures precision diamond abrasive tools, as well as offers chargeable processing services. The company was founded in 1937 and is headquartered in Tokyo, Japan.
Hengan International Group logo

Hengan International Group

OTCMKTS:HEGIY
Hengan International Group Company Limited, an investment holding company, manufactures, distributes, and sells personal hygiene products in the People's Republic of China and internationally. The company offers pocket handkerchiefs, box and soft tissue papers, kitchen towels/papers, toilet rolls, first-aid products, enema, garbage and food bags, preservation papers, table cloths and disposable toilet brush, sanitary napkins, pantiliners, overnight pants, wet tissues, maternal and child care products, adult and baby diapers, and cleansing products. It is also involved in the trading of various products for ladies, pregnant women, infants, and kids, as well as disposable fiber-based products; and engages in the ecommerce business. In addition, the company manufactures and distributes heat and power; and manufactures, distributes, and sells gas, protective equipment, medical instrument, skin care products, antiseptics, and household products. Hengan International Group Company Limited was founded in 1985 and is headquartered in Jinjiang, the People's Republic of China.
Hikma Pharmaceuticals logo

Hikma Pharmaceuticals

OTCMKTS:HKMPF
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.